NMN / NAD+ Precursors for Parkinson's Disease
Also known as: Nicotinamide mononucleotide, NR (Nicotinamide Riboside), NAD+ boosters
Mitochondrial Complex I dysfunction in Parkinson's is linked to NAD+ depletion. Boosting NAD+ may support dopaminergic neuron survival.
Mechanism of Action
In Parkinson's, PINK1 and Parkin mutations impair mitophagy, leading to accumulation of damaged mitochondria. NAD+ restoration supports SIRT3-mediated mitochondrial protein deacetylation, enhances Complex I function, and promotes healthy mitophagy. It also supports dopaminergic neuron-specific energy demands.
General mechanism: NAD+ precursor. Supports mitochondrial function (Complex I), sirtuin activity (SIRT1/3), DNA repair (PARP), and cellular energy metabolism.
Current Evidence
The NADPARK trial (NR in Parkinson's) showed increased NAD+ levels and trends toward improved mitochondrial function. Larger efficacy trials needed. LRRK2 and GBA subtypes may benefit most from metabolic support.
Clinical Status: Phase I/II (NADPARK). NAD+ increase confirmed. Efficacy data preliminary.
Safety Profile
Well-tolerated at studied doses (1-2g/day NMN, 500-2000mg/day NR). No significant adverse effects in human trials. Not regulated as pharmaceuticals.
Key Research Questions
- Does NAD+ boosting particularly benefit PD patients with PINK1/Parkin mutations?
- Can combination with ambroxol (GBA chaperone) address both metabolic and lysosomal PD pathways?